The Efficacy of Carotid Surgery by Subgroups : The Concept of Stroke Prevention Potential by Aro, Ellinoora et al.
Eur J Vasc Endovasc Surg (xxxx) xxx, xxxThe Efﬁcacy of Carotid Surgery by Subgroups: The Concept of Stroke
Prevention Potential5Ellinoora Aro a, Petra Ijäs b,c, Leena Vikatmaa d, Lauri Soinne b,c, Reijo Sund e,f, Maarit Venermo a, Pirkka Vikatmaa a,*a Department of Vascular Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
b Department of Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
c Department of Neurosciences, University of Helsinki, Helsinki, Finland
d Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
e Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
f Centre for Research Methods, Faculty of Social Sciences, University of Helsinki, Helsinki, Finland5 Th
20 Sept
Duodec
* Cor
00029
E-ma
1078
Elsevie
https
Please
EndovWHAT THIS PAPER ADDS
Patient selection should be a key component of carotid surgery reports. A calculator was created where the
presence and recentness of symptoms, sex, increasing stenosis severity, and complication rates could all be
combined into a single ﬁgure. The calculator was tested on real life material and some theoretical inclusion
scenarios. Single hospital treatment development over time and benchmarking between hospitals can be
monitored when registered data includes these parameters, ultimately leading to improved patient selection.Objective: Considering carotid endarterectomy (CEA), reporting treatment delay, symptom status, and surgical
complication rates separately gives an incomplete picture of efﬁcacy; therefore, the aim was to combine
these factors and develop a reporting standard that better describes the number of potentially prevented
strokes. With a real life cohort and theoretical inclusion scenarios, the aim was to explore the stroke
prevention potential of different carotid practices.
Methods: Landmark studies for symptomatic and asymptomatic patients were revisited. By using published
estimates of treatment effect, a simpliﬁed calculator was designed to assess the ﬁve year stroke prevention
rate per 1000 CEAs (stroke prevention potential [SPP], range 0e478), including the presence and recentness
of symptoms, sex, increasing stenosis severity, and complication rates. Patients operated on for carotid
stenosis at Helsinki University Hospital (HUH) between 2008 and 2016 were collected from a vascular registry
(HUSVASC) and categorised according to the model. The local annual complication rate was re-evaluated and
added to the model. The HUH patient cohort was incorporated into the SPP model, and changes over time
analysed. Finally, theoretical changes in patient selection were compared in order to explore the theoretical
impact of patient selection and shortening of the delay.
Results: Fifteen hundred and ﬁve symptomatic and 356 asymptomatic carotid stenoses were operated on with
stroke plus death rates of 3.6% and 0.3%, respectively. The proportion of CEAs performed within two weeks of
the index event increased over the follow up period, being 77% in 2016. The SPP increased from 123 in 2008 to
229 in 2016. Theoretically, 350 ischaemic strokes were prevented in the period 2008e16, with 1861 CEAs.
Conclusions: National and international comparison of different CEA series is irrelevant if the inclusion criteria
are not considered. A calculator that is easy to apply to large scale high quality registered data was
developed and tested. SPP was found to increase over time, which is a probable sign of improved patient
selection and an increased number of strokes prevented by the CEAs performed.Keywords: Benchmarking, Carotid endarterectomy, Registries, Secondary prevention, Stroke, Treatment outcome, Vascular diseases
Article history: Received 24 September 2018, Accepted 7 April 2019, Available online XXX
 2019 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.is manuscript was presented as an abstract at the ESVS Symposium on
ember 2017 in Lyon, France. Parts of this article have been published in
im in the Finnish language, 2018 (duodecim.ﬁ).
responding author. Helsinki University Hospital (HUH), P.O. Box 340,
HUS, Helsinki, Finland.
il address: pirkka.vikatmaa@hus.ﬁ (Pirkka Vikatmaa).
-5884/ 2019 European Society for Vascular Surgery. Published by
r B.V. All rights reserved.
://doi.org/10.1016/j.ejvs.2019.04.003
cite this article as: Aro E et al., The Efﬁcacy of Carotid Surgery by Subgroups:
ascular Surgery, https://doi.org/10.1016/j.ejvs.2019.04.003INTRODUCTION
Carotid endarterectomy (CEA) has been the subject of
several qualiﬁed randomised controlled trials (RCTs) and an
extensive number of post-hoc analyses.1e10 However,
although the information from these studies is readily
available, it is interpreted very diversely in different coun-
tries and guidelines.11e15The Concept of Stroke Prevention Potential, European Journal of Vascular and
2 Ellinoora Aro et al.Patient selection is mainly based on symptom status and
the grade of carotid artery stenosis. High grade (70e99%)
symptomatic stenosis is the most evident indication for
ipsilateral CEA. Operating on symptomatic patients within
two weeks of the event confers maximum beneﬁt from the
procedure. However, in subgroup analysis, the impact of
timing has been least apparent in symptomatic men with
high grade stenosis.16,17
Recommendations for treating asymptomatic patients
are more controversial. The Asymptomatic Carotid Athero-
sclerosis Study (ACAS) and the Asymptomatic Carotid Sur-
gery Trial (ACST) have underpinned the practise guidelines,
although with diverse interpretations. The proportion of
asymptomatic patients varies from 0% to 90% between
countries and from 0% to100% between individual
centres.14,18,19Asymptomatic patients
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Please cite this article as: Aro E et al., The Efﬁcacy of Carotid Surgery by Subgroups:
Endovascular Surgery, https://doi.org/10.1016/j.ejvs.2019.04.003Traditionally, reporting includes the number of symp-
tomatic/asymptomatic patients treated and the annual
complication rates. Since 2004 the importance of operating
promptly has been appreciated increasingly and short delay
is considered to be an independent indicator of good ca-
rotid practice. To date, ﬁve European countries have pub-
lished national data on treatment delay from symptom to
CEA. The median delay is seven days in Sweden (Swedvasc
annual report 2018), nine in Germany, 12 in the UK, and 14
in Norway.20e22 In the Netherlands 75% of the symptomatic
patients are operated on within two weeks.23
Post-hoc analyses of large RCTs (The Carotid Endarter-
ectomy Trialists Collaboration [CETC]) allows estimation of
the number of strokes prevented per 1000 CEAs at ﬁve
years in relation to selected clinical subgroups.16,17,24 By
using the earlier published theoretical absolute riskf strokes prevented at five years by 1000 CEAs
f strokes prevented at five years by 1000 CEAs
Delay – wks
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0 0
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is generated from the number of strokes prevented per
om the published ﬁgures from the major randomised
ade of stenosis, sex, and delay.16,17,24e26 In order to
, the choice was to use zero, when the reported ﬁgure
e number needed to treat was <7, yellow indicates the
tes no strokes prevented (or some strokes caused).
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Stroke Prevention Potential by CEA in Patient Subgroups 3reduction (ARR) for sex, delay, grade of stenosis, and
symptom status (asymptomatic/symptomatic), and by
adding the effect of local complication rate, a calculator was
designed that takes into account all these parameters and
counts the theoretical number of strokes prevented by a
given carotid service. This concept is launched here as the
“stroke preventing potential” (SPP). Investigation of the
evolution of the above mentioned parameters at the au-
thors’ institution from 2008 to 2016 was carried out. Lastly,
theoretical proportions of asymptomatic patients, delays,
and complication rates were included in order to show their
impact on SPP.Table 1. Carotid endarterectomy patients operated on at
Helsinki University Hospital from 2008 to 2016, divided
into relevant subgroups
Characteristic Total (n) Symptomatic Asymptomatic
No. of CEAs 1861 1505 (81) 356 (19)
Sex
Male 1260 (68) 967 (64) 293 (82)
Female 601 (32) 538 (36) 63 (18)
Mean age  SD e y 70.2  8.5 70.8  8.7 67.3  6.7
< 75 1263 (68) 958 (64) 305 (86)
 75 598 (32) 547 (36) 51 (14)
Degree of stenosis e %
50e69 480 (26) 406 (27)
70e99 1381 (74) 1099 (73)
Delay e wks
< 2 791 (53)
2e4 285 (19)
> 4e12 225 (15)
>12 66 (4)
Index date unreliable 138 (9)
Data are n (%) unless otherwise stated. CEA ¼ carotid
endarterectomy.MATERIALS AND METHODS
The results of benchmark RCTs that randomised symptomatic
(North American Symptomatic Carotid Endarterectomy Trial
[NASCET], European Carotid Surgery Trial [ECST]Þ1,2 or asymp-
tomatic (ACAS, ACST)3,4 patients to either conservative or
operative arms were revisited. By using their published esti-
mates of efﬁcacy for selected clinical subgroups (Fig. 1), a
calculator was designed that estimates the ﬁve year stroke
prevention rate per 1000 CEAs performed (SPP).16,17,24e26
Firstly, patients were divided into subgroups by their symp-
tom status (symptomatic/asymptomatic) and by sex. Secondly,
symptomatic patients were further subgrouped by degree of
stenosis d (50e69% and 70e99%) and treatment delay (0e2
weeks, 2e4 weeks, 4e12 weeks, and>12 weeks). In line with
the ACST and ACAS trial results, degree of asymptomatic ste-
nosis subcategories were not introduced. It was assumed that
no asymptomatic patients with<60% stenosis or symptomatic
patients with <50% stenosis were operated on. Borderline
cases were analysed in the moderate stenosis group. With
these speciﬁcations every patient could be placed in a group
representing the potential for stroke prevention (strokes pre-
vented at ﬁve years by performing 1000 CEAs). By calculating
the number of patients in each cell an absolute and propor-
tional number of strokes prevented could be calculated and a
single SPP ﬁgure deﬁned for the whole cohort.
All CEAs performed at Helsinki University Hospital (HUH)
between January 2008 and December 2016 were identiﬁed
from a prospectively collected validated vascular surgery
registry (HUSVASC).27 In order to further improve the quality
of the data and decrease the number of missing data, the
following parameters were double checked from the hospital
electronic patient database or recalculated from images
when inaccurate: symptom status (symptomatic/asymp-
tomatic); grade of ipsilateral carotid artery stenosis (per-
centage); and delay from index symptom to surgery.
Index symptom was deﬁned as the event leading to
consultation and surgery. The grade of stenosis was
assessed by computed tomography angiography (CTA) or
magnetic resonance imaging (MRI) according to the NASCET
method.1 Carotid stenosis was classiﬁed as symptomatic if
the patient had experienced a preceding ipsilateral hemi-
spheric or retinal stroke, transient ischaemic attack (TIA), or
amaurosis fugax in the six months prior to surgery. Patients
with no clear underlying ipsilateral ischaemic retinal orPlease cite this article as: Aro E et al., The Efﬁcacy of Carotid Surgery by Subgroups:
Endovascular Surgery, https://doi.org/10.1016/j.ejvs.2019.04.003hemispheric symptoms were deﬁned as asymptomatic.
Also, patients with uncertain symptoms such as suspicion of
hypoperfusion were classiﬁed as asymptomatic. The peri-
operative events (any stroke or death within 30 days after
surgery) have been evaluated annually as part of the quality
control system at HUH. Each complication was re-assessed
retrospectively from the patient records by a stroke
neurologist and a vascular surgeon. It was not always
possible to determine the delay and these patients were
excluded from the relevant analyses (Table 1).
The template of the ﬁgures used in the calculations is shown
in Fig 1. By using the SPP calculator, the theoretical efﬁcacy of
the carotid service atHUH for theperiod 2008e16was deﬁned.
For comparison, SPP was also calculated for different theoret-
ical patient selection policies. The effect of complication rates
were calculated as follows: the 30 day complication ﬁgures of
6% for symptomatic and 3% for asymptomatic patients were
considered to be the basis for the ﬁgures in Fig 1. By increasing
the effectiveness for each cell with the number of fewer peri-
operative 30 day complications, a novel table for fewer or
zero complication calculations was produced. In case of zero
effect in the original table the ﬁgure was kept at zero and no
negative ﬁgures were used. This was in order to respect the
individual decision making in less evident indications.
Data handling, calculations, and ﬁgures were carried out
with SPSS Statistics 22.0 (IBM, Armonk, NY, USA) and the
SPP calculator in Excel v16.0 (Microsoft, Redmond, WA,
USA).RESULTS
In total, 1861 CEAs were performed at HUH between 1
January 2008 and 31 December 2016. Over this time period
the annual number of CEAs increased by 32%. The operated
stenosis was symptomatic in 1505 (81%) patients andThe Concept of Stroke Prevention Potential, European Journal of Vascular and
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Figure 3. Time from index event to surgery. Distribution of
symptomatic patients into the following delay groups (from index
event to carotid endarterectomy) < 2, 2e4, 4e12, and >12
weeks from 2008 to 2016. CEA ¼ carotid endarterectomy.
4 Ellinoora Aro et al.asymptomatic in 356 patients (19%). The annual proportion
of asymptomatic patients ranged from 11% to 31%, with no
signiﬁcant trend (Fig. 2).
The mean  SD age of the patients was 70.2  8.5 years;
68% were male. Asymptomatic patients were younger and
more often male. In symptomatic patients, the degree of
stenosis was severe (70e99%, according to the NASCET
method)1 in 73% of the cases (Table 1). Regarding the index
event in symptomatic patients, most common was minor
stroke (42%) or TIA (35%). With four exceptions calculated
to have a 55% stenosis, all operated asymptomatic stenoses
were >60%.
The time from index event to surgery was reliably
obtainable for 1367 (91%) symptomatic patients. Median
time from index event to surgery was 12 days (interquartile
range 7e24 days). The detailed distribution of patients to
different categories is shown in Table 1. In 2008, 18% un-
derwent CEA within the two weeks, while in 2016 this
proportion had increased to 77% (Fig. 3).
For symptomatic patients, the combined 30 day
stroke and death rate was 3.6% (n ¼ 54; yearly range
2.0e6.7%) (Fig. 4). Forty-three suffered a non-fatal
ischaemic or haemorrhagic stroke. Of the 11 deaths,
all of which occurred after discharge, two were classi-
ﬁed to have been caused by an ischaemic stroke and
one by a haemorrhagic stroke, four had cardiac causes,
and in four patients the reason remained unknown. Of
all asymptomatic patients, the combined stroke and
death rate was 0.3% (n ¼ 1); one patient with a
contralateral occlusion developed a hyperperfusion
syndrome and was treated for low blood pressure in a
stroke unit but eventually died of a haemorrhagic
stroke.
The SPP for the period 2008e16 at HUH was 188
(strokes potentially prevented by performing 1000 op-
erations in ﬁve years of follow up) when all patients
and the actual complication rates were taken into
consideration. The development of the SPP index during
the study period is illustrated in Fig. 5. If theoretically
no complications would have occurred, the SPP would0
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Figure 2. The annual number of symptomatic and asymptomatic
patients operated on for carotid stenosis between 2008 and 2016.
In 19% the indication for surgery was an asymptomatic stenosis.
CEA ¼ carotid endarterectomy.
Please cite this article as: Aro E et al., The Efﬁcacy of Carotid Surgery by Subgroups:
Endovascular Surgery, https://doi.org/10.1016/j.ejvs.2019.04.003have increased to 215, and with the 6% complication
rate as in NASCET/ECST for symptomatic and 3% as in
ACST for asymptomatic patients, the SPP would have
been 166 (Fig. 5). By excluding asymptomatic patients,
but keeping the characteristics of symptomatic patients
at HUH in the calculation, the SPP would have been
220. If the annual proportions of asymptomatic patients
were 50% or 90%, the SPP would have been 141 and
78, respectively (Fig. 6A). The effect of theoretical time
delays is demonstrated in Fig. 6B. If all the symptomatic
patients in the HUH 2008e16 CEA cohort were oper-
ated on within two weeks, keeping the same sex dis-
tribution and proportions of high and moderate grade
stenosis, the SPP would have been 2.2 times higher
than if the operations were carried out after 12 weeks’
delay (SPPs of 239 and 109, respectively).DISCUSSION
SPP includes symptom status (symptomatic/asymptom-
atic), grade of ipsilateral carotid stenosis, sex, delay
from index symptom to surgery, and local complication0.0 
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Figure 4. Annual rates of stroke/death for symptomatic patients
within 30 days. There were no strokes and one post-operative
death (0.3%) in the asymptomatic group.
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changes the number of potentially prevented strokes. The (A)
proportion of asymptomatic patients and (B) delay from symptom
to surgery have a paramount impact on the stroke prevention
potential (SPP). The effect of delay in (B) is calculated using the
symptomatic patients operated on at Helsinki University Hospital
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ate grade stenosis. The higher SPP for longest delay is explained
by the high proportion of men. SPP¼ stroke prevention potential,
strokes prevented at 5 years by performing 1000 carotid
endarterectomies.
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Helsinki University Hospital (HUH). The three lines represent
different possible complication levels, calculated separately for
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complication levels (asymptomatic/symptomatic) were 0%/0%,
actual annual HUH levels, and for 3%/6%, respectively.
Stroke Prevention Potential by CEA in Patient Subgroups 5rate. These factors are mostly well documented, un-
ambiguous, easily collected, and incorporated into
vascular registries. Thus, SPP could be a relatively sim-
ple method when assessing the institutional carotid
service and when comparing national and international
data.
Delay and sex
According to the analyses by CETC, operating on symp-
tomatic patients within two weeks of the event results in
18.5% absolute risk reduction (ARR) in the stroke rate at ﬁve
years, while after 12 weeks the ARR is only 0.8%.16 Women
were shown to beneﬁt most when CEA was carried out
within two weeks, with a rapid decline in beneﬁt with the
passage of time since the event. However, in men, partic-
ularly those with high grade stenosis, the efﬁcacy of CEA in
preventing strokes was clearly evident even after longer
delays.17 The index event is the one that got the patient to
seek medical advice and this event is recorded prospectively
into the HUSVASC register.28
CECT calculations are based on old RCTs that randomised
the patients two decades ago; however, even in the era of
modern medical treatment the incidence of recurrent
events remains high. In a combined analysis of two vascular
registries and one population based study, including
symptomatic patients awaiting CEA on modern stroke pre-
vention medication, the risk of ipsilateral stroke or retinal
artery occlusion was 2.7% (1 day), 5.3% (3 days), 11.5% (14
days), and 18.8% (90 days).29 In a series of operations after
thrombolysis, seven of 128 (5.5%) patients had a recurrent
stroke prior to surgery a median of four days (interquartile
range 0e8 days) after the thrombolysis, whereas the 30 day
peri-/post-operative stroke rate was six of 128 (4.7%).30 This
means that operating promptly remains important, despite
improved medication.
At HUH, continuous efforts in decreasing the delay to
surgery have resulted in more rapid access to carotid sur-
gery. The median delay over the study period was 12 days,
bears international comparison, and improved over time.Please cite this article as: Aro E et al., The Efﬁcacy of Carotid Surgery by Subgroups:
Endovascular Surgery, https://doi.org/10.1016/j.ejvs.2019.04.003Yet, in 2016, 23% of symptomatic patients did still not
receive surgical treatment in time. This was mostly as a
result of the lack of patient awareness in seeking urgent
medical advice, but delay in the diagnostics still occur.28,31
The two week recommendation is obtained from post-hoc
analysis and has not been evaluated in RCTs.Grade of stenosis and plaque characteristics
Symptomatic patients with high grade stenosis (70e99%)
beneﬁt more from the CEA than those with moderate (50e
69%) stenosis.24 In asymptomatic patients, the risk reduc-
tion becomes evident in stenosis 60%, but no further
beneﬁt is gained with increasing degree of stenosis.3,4 In the
original RCTs for symptomatic patients the stenosis severity
was measured from digital subtraction angiography, while
ACST accepted diagnosis by duplex ultrasound (DUS) alone.
Today, the measurement and decision making mostly rely
on CTA and/or magnetic resonance angiography imag-
ing.32,33 Other imaging features, such as plaque area on
computerised plaque analyses,34 intraplaque haemorrhageThe Concept of Stroke Prevention Potential, European Journal of Vascular and
6 Ellinoora Aro et al.on MRI35 and plaque lucency on DUS,36 may identify sub-
groups of patients that are at increased risk of stroke. So far,
these characteristics are too elusive to be incorporated into
a calculator.Asymptomatic stenosis
ACST reported an overall ﬁve year risk of recurrent stroke of
6.4% in the surgical group vs. 11.8% in medical group, with
women having a lower ARR than men (4.1% vs. 8.2%,
respectively).4 A meta-analysis of data from ACAS and ACST
showed a beneﬁt of CEA for men but not for women or for
any patient older than 75 years regarding ﬁve year risk of
any stroke or peri-operative death.25,26 When the ACST
continued follow up until 10 years an ARR of 4.6% was
observed in both sexes, which can be reported as 46Asymptomatic patients
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Figure 7. Patients (n ¼ 1861) who had a carotid end
between 2008 and 2016. In order to get a stroke preventin
designated their own potential prevention number. This
general complication rate. HUH ¼ Helsinki University Hosp
potential, strokes prevented at 5 years by performing 1000
Please cite this article as: Aro E et al., The Efﬁcacy of Carotid Surgery by Subgroups:
Endovascular Surgery, https://doi.org/10.1016/j.ejvs.2019.04.003prevented strokes per 1000 patients operated on.5 Stroke
rates among asymptomatic patients on modern best med-
ical treatment have declined since the original RCTs, and
common criticism questions the validity of the results
today.15 In order to maintain coherence, the decision was
made to use the ARRs derived from the ﬁve year follow up
for both symptomatic and asymptomatic patients. This
compromise may underestimate the efﬁcacy of operating
asymptomatic women.Complications
When assessing the quality of the carotid service, the local
complication rate should be proportional to patient selec-
tion and delays. Operating on low risk patients with minimal
complications provides tidy statistics, but more strokes areients (%) operated on at HUH 
ents (%) operated on at HUH 
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number could then be manipulated according to the
ital; NA ¼ delay not available. SPP ¼ stroke prevention
carotid endarterectomies.
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Stroke Prevention Potential by CEA in Patient Subgroups 7prevented when focusing the operations on high risk
symptomatic patients. This is highlighted by the fact that, in
the present study, 0.3% and 3.6% of asymptomatic and
symptomatic patients, respectively, suffered a stroke or
died.
Vascular registries and risk calculators
Modern quality control requires hospitals to maintain
proper registries of the operations performed. Standardised
and validated vascular registries enable national and inter-
national comparison and fair benchmarking. In the future,
SPP or a related efﬁcacy index should be incorporated into
registry reporting. A model to estimate the ﬁve year stroke
risk for each individual patient with a symptomatic carotid
stenosis has been developed (www.ndcn.ox.ac.uk). The
model is beneﬁcial in daily decision making but not appli-
cable to large scale registry data.
Limitations
The SPP concept has some limitations. Firstly, the model is
based on relatively old RCT data, which may not be fully
valid today. The predictive value of the individual variables
may be updated to the model as soon as ongoing RCTs (e.g.,
Carotid Revascularisation Endarterectomy vs. Stenting Trial-
2 [CREST-2], ECST-2, and ACST-2) are ﬁnalised and results
published. For example, if the effect of surgery is halved the
SPP number may simply also be halved in order to get a
more accurate estimate. Secondly, the model comprises
only some variables and fails to take into account well
known plaque and patient related details like the nature of
the symptom, possibly causing a signiﬁcant problem in case
mix.11 However, when dealing with large registry data,
simpliﬁcation could be regarded as a strength rather than a
weakness of the model.
Thirdly, a high SPP number should not be interpreted
directly as a sign of effective and recommendable carotid
practice. For example, the highest SPP (478) would be ob-
tained by operating only on symptomatic females within
two weeks of the index event with no complications, which
would lead to exclusion of the largest group of patients,
males with a high grade stenosis (46% in the present series).
The minimum was set to zero, but patients operated on
outside the recommended indications should always be
reported (Fig. 7). The authors chose to exclude carotid
stenting because it is rarely performed in the authors’ unit
owing to the fact that large scale RCT data has demon-
strated CEA superiority in the most important subgroup,
symptomatic patients with a short delay.
Some statistical issues remain in the SPP calculator. In
principle, SPP is only a justiﬁed weighted average based on
available data and extracted evidence from RCTs. For the
actual comparisons it would be beneﬁcial to provide some
conﬁdence intervals or other measure of uncertainty. Some
assumptions had to be made to keep the calculator simple
and because of the limited information available in pub-
lished RCTs. Most importantly, it was assumed that the
subgroups are independent of each other. For example thePlease cite this article as: Aro E et al., The Efﬁcacy of Carotid Surgery by Subgroups:
Endovascular Surgery, https://doi.org/10.1016/j.ejvs.2019.04.003grade of stenosis should not have had any systematic
impact on delay in the original publications, because
otherwise some part of the beneﬁt may be accounted for
twice. This needs to be acknowledged, but it does not
invalidate the SPP calculations. Another assumption that
had to be made was that there were no censored obser-
vations in published cumulative complication rates. This
may have a minor impact on the recalculations of the
impact of different local complication proportions. This er-
ror was estimated to be <1%.
SPP seems a promising tool for benchmarking. Owing to
the fact that the original calculations are based on post-hoc
analysis, the SPP result should not be seen as an absolute
ﬁgure, but rather as a tool for assessing the quality of the
carotid service over time and between units.
CONCLUSIONS AND RELEVANCE
The SPP summarises the main ﬁndings of the RCTs that have
given a solid basis for CEA practice guidelines today. The SPP
ﬁgure (a summary of symptom, delay, sex, grade of stenosis,
and complications representing strokes prevented per 1000
operations over ﬁve years of follow up) serves as a com-
parison tool over time and between hospitals, regions, and
countries, providing that reliable data are registered. It is
hoped that, in the future, inclusion criteria reporting could
be a requirement when CEA results are reported. Ideally,
SPP should be implemented in all vascular registries in order
to make benchmarking more accurate.
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